Connor, Clark & Lunn Investment Management (CC&L)
FOMX

Connor, Clark & Lunn Investment Management (CC&L)’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-29,055
Closed -$166K – 1099
2018
Q3 		$166K Buy
+29,055
New +$166K ﹤0.01% 863

Other funds holding FOMX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s FOMX Position: Q4 2018 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q4 2018, closing a stake of 29,055 shares — an estimated $166K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in FOMX in Q3 2018 and held it in 1 quarter. The position peaked at $166K in Q3 2018. 66 funds tracked by Wall St. Rank hold FOMX as of Q4 2018.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q4 2018 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 29,055 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q4 2018, an estimated $166K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2018 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $166K in Q3 2018.
  • 66 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q4 2018.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2018, filed 12 Feb 2019.